Clinical Trial Update: An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia [EARLY_Phase 1]

View source ↗

Summary

This clinical trial is an early-phase study evaluating CD19 CAR NK cells for treating refractory primary immune thrombocytopenia (alloimmune thrombocytopenia) a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alloimmune Thrombocytopenia
• Immune Thrombocytopenia

Drugs mentioned

• CD19 CAR NK cells (CD19 CAR NK cell therapy)

Snippet

Sponsor: Changzhou No.2 People's Hospital | Conditions: Thrombocytopenia Alloimmune | EARLY_Phase 1 | Status: RECRUITING